Advanced/Metastatic Tumors clinical trials at UC Cancer

• Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab With and Without Chemotherapy in Locally Advanced or Metastatic Tumors

  open to eligible people ages 18 years and up

  This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of MTIG7192A alone or in combination with atezolizumab administered with and without chemotherapy in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

  at UCLA

Last updated: November 12, 2020